• The New Era of Biologic Therapies to Treat Patients with COPD: Best Practices for the Pulmonologist

    Supported by an independent educational grant from AstraZeneca

  • 1. Which pairing of a COPD biologic with its mechanism of action is correct?*
  • 2. According to the current GOLD report, which of the following remains mandatory to confirm a diagnosis of COPD, despite the new emphasis on pre-bronchodilator screening?*
  • 3. Based on recent phase 3 data in eosinophilic COPD, which biologic has NOT demonstrated clear clinical benefit?*
  • 4. A patient with COPD, chronic bronchitis, and 2 moderate exacerbations in the past year despite adherent triple inhaled therapy has a blood eosinophil count of 320 cells/µL confirmed on two occasions. Which statement best reflects current practice for biologic selection?*

  • Management of Patients with Non-Cystic Fibrosis Bronchiectasis: Reducing Burden of Disease and Addressing Exacerbation and Lung Function

    Supported by an independent educational grant from Insmed

  • 5. Per current CHEST/ERS bronchiectasis guidelines, which long-term therapy is recommended as first-line for adults with NCFBE who are not colonized with Pseudomonas aeruginosa but have ≥2–3 exacerbations/year despite optimized airway clearance?*
  • 6. A subgroup analysis of ASPEN trial participants of Asian race found that brensocatib's effects on exacerbation rate, lung function, and safety were:*
  • 7. Which of the following best reflects a collaborative, multidisciplinary best practice for optimizing outcomes in a patient with NCFBE?*

  • RSV Vaccinations: Safeguarding the Health of Older Adults with Pulmonary-Associated Comorbidities

    Supported by an independent educational grant from GSK

  • 8. Among adults hospitalized with RSV infection, which comorbid pulmonary condition is associated with the highest reported prevalence and complication rate?*
  • 9. In 2025, ACIP expanded its RSV vaccination recommendation to include which additional group?*
  • 10. What is a current best practice for administering RSV vaccine to an eligible patient with chronic pulmonary disease?*

  • The New Era of Biologic Therapies to Improve Outcomes in Patients With Severe Asthma

    Supported by an independent educational grant from GSK

  • 11. IL-5 contributes to the pathophysiology of severe eosinophilic asthma primarily through which mechanism?*
  • 12. Which blood eosinophil threshold, combined with exacerbation history, is commonly used in clinical trials and practice to identify candidates for anti-IL-5/IL-5Rα biologic therapy in severe asthma?*
  • 13. Which comorbidity has been most consistently and independently associated with poor symptom control in patients with severe asthma?*
  • 14. Despite biologics showing similar real-world efficacy in reducing exacerbations across racial groups, retrospective studies have identified which disparity in severe asthma care?*
  • What is your license?*
  • What is your specialty?*
  • What is your practice setting?*

  • Please rate the extent to which this activity met the following objectives:

  • Learning Objectives
    Rows
  • Do you feel this activity was fair balanced and free of commercial bias?
  • This educational activity will result in a change in my role as a healthcare team member.
  • This educational activity will result in a change in my practice behavior.
  • Based on your participation in this activity, choose the statement(s) that applies to how your role as a healthcare team member will change:
  • Attestation to time spent on activity: AcademicCME designates this live activity for a maximum of 2.5 AMA PRA Category 1 Credits™.

  • AcademicCME thanks you for your participation in this activity. All information provided improves the scope and purpose of our programs.

  • Should be Empty: